With the establishment of robust TFPI2 quantification assays, it has become evident that circulating concentrations of TFPI2 are markedly elevated in ovarian cancer, as well as in endometrial and renal cell carcinomas [17,18,19]. This evidence concerns the gene TFPI2 and renal cell carcinoma.